Get started
DexCom, Inc.DexCom, Inc.DexCom, Inc.

DexCom, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

DXCM chart


Full chart

DXCM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪29.61 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
45.45
Basic EPS (TTM)
1.74 USD
Net income (FY)
‪541.50 M‬ USD
Revenue (FY)
‪3.62 B‬ USD
Shares float
‪385.65 M‬
Beta (1Y)
0.47

Employees


Employees (FY)
‪9.6 K‬
Change (1Y)
‪+2 K‬ +26.32%
Revenue / Employee (1Y)
‪377.32 K‬ USD
Net income / Employee (1Y)
‪56.41 K‬ USD

About DexCom, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Kevin Ronald Sayer
Website
dexcom.com
Headquarters
San Diego
Founded
1999
FIGI
BBG000QTF8K1
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

DXCM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

DXCM highest yielding bonds


DXCM5195221
DexCom, Inc. 0.25% 15-NOV-2025
Yield to maturity
5.44%
Maturity date
Nov 15, 2025
DXCM5813816
DexCom, Inc. 0.375% 15-MAY-2028
Yield to maturity
4.32%
Maturity date
May 15, 2028

Explore more bonds 

Frequently Asked Questions


The current price of DXCM is 80.04 USD — it has increased by 5.83% in the past 24 hours. Watch DexCom, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange DexCom, Inc. stocks are traded under the ticker DXCM.
DXCM stock has risen by 2.09% compared to the previous week, the month change is a 7.37% rise, over the last year DexCom, Inc. has showed a −32.51% decrease.
We've gathered analysts' opinions on DexCom, Inc. future price: according to them, DXCM price has a max estimate of 125.00 USD and a min estimate of 75.00 USD. Watch DXCM chart and read a more detailed DexCom, Inc. stock forecast: see what analysts think of DexCom, Inc. and suggest that you do with its stocks.
DXCM reached its all-time high on Nov 18, 2021 with the price of 164.86 USD, and its all-time low was 0.34 USD and was reached on Nov 20, 2008. View more price dynamics on DXCM chart.
See other stocks reaching their highest and lowest prices.
DXCM stock is 8.00% volatile and has beta coefficient of 0.47. Track DexCom, Inc. stock price on the chart and check out the list of the most volatile stocks — is DexCom, Inc. there?
Today DexCom, Inc. has the market capitalization of ‪31.26 B‬, it has decreased by −3.32% over the last week.
Yes, you can track DexCom, Inc. financials in yearly and quarterly reports right on TradingView.
DexCom, Inc. is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
DXCM earnings for the last quarter are 0.45 USD per share, whereas the estimation was 0.43 USD resulting in a 3.56% surprise. The estimated earnings for the next quarter are 0.52 USD per share. See more details about DexCom, Inc. earnings.
DexCom, Inc. revenue for the last quarter amounts to ‪994.20 M‬ USD, despite the estimated figure of ‪990.44 M‬ USD. In the next quarter, revenue is expected to reach ‪1.10 B‬ USD.
DXCM net income for the last quarter is ‪134.60 M‬ USD, while the quarter before that showed ‪143.50 M‬ USD of net income which accounts for −6.20% change. Track more DexCom, Inc. financial stats to get the full picture.
No, DXCM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has ‪9.60 K‬ employees. See our rating of the largest employees — is DexCom, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DexCom, Inc. EBITDA is ‪840.40 M‬ USD, and current EBITDA margin is 21.64%. See more stats in DexCom, Inc. financial statements.
Like other stocks, DXCM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DexCom, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DexCom, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DexCom, Inc. stock shows the sell signal. See more of DexCom, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.